Clinical Trials Browser

Active not recruiting × Interventional × 3-Iodobenzylguanidine × Clear all

NCT04385277 2025-10-27

Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL)

Phase 2 Active not recruiting

41 enrolled 13 charts

Neuroblastoma, Ganglioneuroblastoma

NCT02378428 2025-05-13

MIBG

Phase 2 Active not recruiting

Neuroblastoma

NCT03044977 2023-08-16

Study to Evaluate the Safety of Combining Two Radionuclide Therapies to Treat Mid-gut Neuroendocrine Tumors

Phase EARLY_PHASE1 Active not recruiting

Neuroendocrine Tumors